Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2011	Sep. 30, 2010
Current:
Cash and cash equivalents	$ 38,701	$ 22,922
Restricted cash	60	150
Marketable securities, available for sale		6,001
Taxes receivable	35	116
Other receivable	1	11
Prepaid and other assets	399	365
Total current assets	39,196	29,565
Property and equipment, net	2,253	2,998
Intellectual property, net	49	53
Long term other assets	7
Total assets	41,505	32,616
Current:
Accounts payable	222	1,989
Accrued expenses:
Clinical trial expenses	763	1,362
Payroll and related	1,118	357
Accounting and legal fees	191	300
Severance	688
Other	204	334
Income taxes payable	103	45
Total current liabilities	3,289	4,387
Common stock warrant liability	996	4,169
Severance payable, long term portion	142
Total liabilities	4,427	8,556
Commitments
Stockholders' equity:
Convertible preferred stock, $.01 par value; 50,000,000 shares authorized, none and 1,813,944 issued and outstanding	18
Common stock, $.01 par value; 100,000,000 shares authorized; 26,399,764 and 38,647,683 issued and outstanding	386	264
Additional paid-in capital	212,020	188,549
Accumulated other comprehensive loss		1
Deficit accumulated during the development stage	(175,346)	(164,754)
Total stockholders' equity	37,078	24,060
Total liabilities and stockholders' equity	$ 41,505	$ 32,616